Results 61 to 70 of about 333,660 (389)

Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy.

Gastroenterology, 2019
BACKGROUND & AIMS Hepatocellular carcinoma (HCC) is often associated with hepatitis B virus (HBV) infection. Cells of most HBV-related HCCs contain HBV-DNA fragments that do not encode entire HBV antigens. We investigated whether these integrated HBV-DNA
A. Tan, N. Yang, Thinesh Lee Krishnamoorthy, V. Oei, A. Chua, Xinyuan Zhao, Hui Si. Tan, A. Chia, N. Le Bert, Diana H. P. Low, H. Tan, Rajneesh Kumar, F. Irani, Z. Ho, Qi Zhang, E. Guccione, L. Wai, S. Koh, W. Hwang, W. Chow, A. Bertoletti   +20 more
semanticscholar   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

The enzymes LSD1 and Set1A cooperate with the viral protein HBx to establish an active hepatitis B viral chromatin state [PDF]

, 2016
Indexación: Web of ScienceWith about 350 million people chronically infected around the world hepatitis B is a major health problem. Template for progeny HBV synthesis is the viral genome, organized as a minichromosome (cccDNA) inside the hepatocyte ...
Alarcon, V, Alvarez, F, De Ferrari, GV, Flores, Y, Hernandez, S, Kann, M, Loyola, A, Rubio, L, Varas-Godoy, M, Villanueva, RA   +9 more
core   +2 more sources

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.

Blood, 2019
Risk of hepatitis B virus (HBV) reactivation was assessed in B-cell non-Hodgkin lymphoma (NHL) patients with resolved HBV infection (hepatitis B surface antigen negative, hepatitis B core antibody positive) who received obinutuzumab- or rituximab ...
S. Kusumoto, L. Arcaini, X. Hong, Jie Jin, W. Kim, Y. Kwong, M. Peters, Yasuhito Tanaka, A. Zelenetz, H. Kuriki, G. Fingerle-Rowson, T. Nielsen, E. Ueda, Hanna Piper-Lepoutre, G. Sellam, K. Tobinai   +15 more
semanticscholar   +1 more source

Nonsynonymous C1653T Mutation of Hepatitis B Virus X Gene Enhances Malignancy of Hepatocellular Carcinoma Cells

Journal of Hepatocellular Carcinoma, 2022
Cuifang Zhang,1,2 Ying Xie,3 Ruixue Lai,1 Jianhua Wu,4 Zhanjun Guo1 1Department of Rheumatology and Immunology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China; 2Department of Oncology, The Pingshan County People’
Zhang C, Xie Y, Lai R, Wu J, Guo Z
doaj  

Anti-HBV effect of TAT- HBV targeted ribonuclease

World Journal of Gastroenterology, 2003
To prepare and purify TAT-HBV targeted ribonuclease fusion protein, evaluate its transduction activity and investigate its effect on HBV replication in 2.2.15 cells.The prokaryotic expression vector pTAT containing TR gene was used in transforming E.coli BL21 (DE3) LysS and TR was expressed with the induction of IPTG.
Yinghui Li, Jun Liu, Jin Ding, Ya Zhao, Cai-Fang Xue, Wei-Dong Gong   +5 more
openaire   +3 more sources

Evaluación del desempeño de modelos hidrológicos GR4J, HBV y SOCONT para el pronóstico de caudales medios diarios en la cuenca del río Ramis, Perú [PDF]

Revista Ingeniería UC, 2020
Las inundaciones son fenómenos naturales que han ocurrido a lo largo de la historia. La frecuencia con la que se presentan ha inducido importantes pérdidas humanas, pérdidas en la agricultura, el sistema socioeconómico y daños a la infraestructura ...
Efrain Lujano, Jesús David Sosa, Rene Lujano, Apolinario Lujano   +3 more
doaj  

Imeglimin attenuates liver fibrosis by inhibiting vesicular ATP release from hepatic stellate cells

FEBS Letters, EarlyView.
Imeglimin, at clinically relevant concentrations, inhibits vesicular ATP accumulation and release from hepatic stellate cells, thereby attenuating purinergic signaling and reducing fibrogenic activation. This mechanism reveals a newly identified antifibrotic action of imeglimin beyond glycemic control.
Seiji Nomura, Lixiang Wang, Nao Hasuzawa, Ayako Nagayama, Sawako Moriyama, Kenji Ashida, Yoshinori Moriyama, Masatoshi Nomura, Ken Yamamoto   +8 more
wiley   +1 more source

Interleukin‐6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal Analyses

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited ...
Jonathan Pini, Emanuela Martinuzzi, Sandra Dhifallah, Abderhmane Slioui, Angela Puma, Luisa Villa, Michele Cavalli, Andra Ezaru, Jérémy Garcia, Manuela Gambella, Federico Torre, Luca Jacopo Pavan, Nicolas Glaichenhaus, Sabrina Sacconi   +13 more
wiley   +1 more source

Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic Hepatitis B virus infected patients [PDF]

, 2012
Natural killer (NK) cells play a critical role in innate antiviral immunity, but little is known about the impact of antiviral therapy on the frequency of NK cell subsets.
Chi, X., Hou, J., Hu, X., Jin, Q., Lv, J., Niu, J., Pan, Y., Sun, H., Tian, Z., Tu, Z., Xiao, W., Xu, D., Yan, H.   +12 more
core   +3 more sources